Like Lou Grant, Larry Birger, however, was as talented as he was cantankerous, and his hard-boiled approach rubbed off. Although Herb is a cupcake in comparison when it comes to demeanor, the RealMoney.com senior columnist has that same kind of drive and intensity as Birger when it comes to investigative business reporting. If I were the CEO of a big company, the last people I'd want to see at my front door first thing in the morning would be Greenberg and a 60 Minutes video crew.

On Nov. 30, for example, Herb was thumbing through The Wall Street Journal when he noticed an ad on Page A-5 from Fidelity Investments, in which Fidelity boasted about the phenomenal growth of 14 funds over one, five and 10 years. What caught his eye -- and nobody else's -- was that the funds' performances were as of Sept. 30. A lot has happened in the market since then, so he checked those numbers against the year-to-date figures.

In his Dec. 1 column, Is Fidelity Making Itself Look Better Than It Is? , Greenberg reported that the answer was a resounding yes. In The Wall Street Journal ad, Fidelity reported that its New Millenium Fund (FMILX: - news - boards) had a one-year return of 65.5%. As of Nov. 29, however, that same fund's year-to-date return was off nearly 12%. In fact, all 14 funds were down since Sept. 30, some remarkably so.

That column was a revelation. But in all fairness, Herb was humming all week:

On Nov. 30, in Lessons of Lernout , Greenberg returned to one of his favorite haunts, Lernout & Hauspie (LHSP:Nasdaq - news - boards).

Herb had a hunch something was wrong and was hot on Hauspie's trail early on. He took lots of unwarranted heat, but his stories were confirmed to be true once and for all on Nov. 29 when the software speech-recognition firm from Belgium filed for Chapter 11 .

In Lessons of Lernout, Greenberg listed 11 reasons for investors to be wary, including a rapidly rising stock price, companies that don't take calls from journalists, and foreign firms that file only the minimum required financial statements with the SEC.

On the same day, Herb also pointed out a number of reasons why Gateway's (GTW:NYSE - news - boards) sudden shortfall should been no surprise . According to Greenberg, there were warnings on top of warnings for everyone to see.

One of the joys of writing The Best of RealMoney is that it makes me peruse each day's submissions to RealMoney.com more carefully. The emails I receive from readers about their weekly favorites -- I'm glad to hear from you at marty.klinkenberg@thestreet.com -- also help when it comes to writing this regular Saturday feature.

This week, I believe, was the Web site's strongest since this column made its debut on Nov. 4 . Because of that, it's hard to pick only a few highlights.

Todd Harrison is always a favorite of readers, and the glossary that he provided on Nov. 30 was fun. Are you having a drekky day? Do you think Elmer's next move will leave investors unglued? Is the thought starting to make you schvitz. If you aren't sure, give Todd-O a look.

Because I really have no clue where the market is heading, I love pieces that point out stocks or sectors in which money is being made.

Because of that, I enjoyed Jim Cramer's Stayin' Alive With the New High List on Nov. 27. The fact that somebody is being rewarded when I get a burger at Wendy's (WEN:NYSE - news - boards) almost turns eating fast food into a selfless act.

For those who missed it, some of JJC's other favorite stocks to consider include Philip Morris (MO:NYSE - news - boards), General Dynamics (GD:NYSE - news - boards), Toll Brothers (TOL:NYSE - news - boards) and Pulte (PHM:NYSE - news - boards). And while I'm at it, I might as well wash down that spicy chicken sandwich with a Coors (RKY:NYSE - news - boards). Again, a selfless act.

Don Luskin waded in similarly on Nov. 28 with Ideas From the Bottom of the Barrel , a piece on stocks from out-of-favor sectors that may be worth buying while everyone else is selling. Clarent (CLRN:Nasdaq - news - boards), a software company whose stock has gone from $178 last March to $14 last week, is one of five companies Luskin mentions.

Another reader favorite, Lissa Morgenthaler, suggested on Nov. 28 that biotech indices, which tested support recently at their 300-day moving averages, will continue trending higher. And in For Biotech, This Time It's Different , she made a case for it by pointing out that the stocks of companies producing monoclonal antibodies have skyrocketed.

Lastly, columnist Bill Meehan deserves kudos not for any column in particular, but for a string of terrific predictions about the Nasdaq's many ups and downs in recent days. Figuring that out over the long term is difficult enough. But from day to day? That's nuts.

I wonder if he knows anything about horse racing?

Note: Thanks to telecom reporter and television junkie Carolyn Koo, and editors Sam (Night Stalker) Graff and Stacy Willits for help with the poll.

Send letters to the editor to letters@realmoney.com.
Read our conflicts and disclosure policy.
Order reprints of RealMoney.com articles.	Top
Research Now on DLJdirect GD LHSP MO Visit the DLJdirect Research Center

RELATED STORIES
	Commentary Features The Best of RealMoney: Isn't There Anyone Else?11/24/00 6:29 PM ET Are we really stuck with one of these two guys? Can any airline get you where you are going on time? And, are chads really so bad? Commentary Features The Best of RealMoney: He'll Be Sorry11/18/00 7:01 AM ET Why the winner of the White House race will wish he hadn't emerged triumphant. And take our post-election poll. Commentary Features Wake Me When the Election Is Over, and the Best of RealMoney 11/11/00 12:33 PM ET Read why Don Luskin was talking to himself all night, and take a poll about Election Night.